ASNS
Actelis Networks Inc.NASDAQTECHNOLOGYCOMMUNICATION EQUIPMENT
Key Statistics
Market Cap
$9.23M
P/E Ratio
—
EPS
$-5.68
Beta
1.43
52W High
$8.60
52W Low
$0.17
50-Day MA
$0.35
200-Day MA
$3.14
Dividend Yield
—
Profit Margin
-225.00%
Forward P/E
—
PEG Ratio
—
About Actelis Networks Inc.
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to treat infectious diseases. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.67M |
| Gross Profit (TTM) | $1.22M |
| EBITDA | $-7.17M |
| Operating Margin | -117.00% |
| Return on Equity | -212.30% |
| Return on Assets | -50.60% |
| Revenue/Share (TTM) | $2.52 |
| Book Value | $0.59 |
| Price-to-Book | 1.98 |
| Price-to-Sales (TTM) | 2.51 |
| EV/Revenue | 1.762 |
| EV/EBITDA | -0.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 28.60% |
| Shares Outstanding | $26.72M |
| Float | $26.60M |
| % Insiders | 5.91% |
| % Institutions | 5.53% |
Analyst Ratings
Consensus ($3.00 target)
1
BuyData last updated: 4/7/2026